pagibaximab
mAbexperimental
Pagibaximab is a chimeric monoclonal antibody for the prevention of staphylococcal sepsis in infants with low birth weight. As of March 2010, it is undergoing Phase II/III clinical trials. — Wikipedia
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Apr 1, 2001 (NCT00636285)
Timeline
Indications
Studied for
Mechanism of action
- Lipoteichoic acidINHIBITOR
Lipoteichoic acid inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPagibaximab ↗
- ChEMBLCHEMBL2108042 ↗
Also known as
- a110
- a110
- bsyx-a110
- bsyx-a110
- bsyx-a110
- pagibaximab
- pagibaximab
- pagibaximab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00646399 | Phase 2/Phase 3 (Phase 3) | Mar 1, 2009 | Biosynexus Incorporated |
| NCT00631800 | Phase 2 | May 1, 2003 | Baylor University, Biosynexus Incorporated, GlaxoSmithKline |
| NCT00631878 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2001 | Baylor University, Biosynexus Incorporated, GlaxoSmithKline |
| NCT00636285 | Phase 1 | Apr 1, 2001 | Baylor University, Biosynexus Incorporated |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biosynexus Incorporated | For profit | 4 | 4 | 3 | 2001 |
| Baylor University | Academic/Hospital | 3 | 0 | 2 | 2001 |
| GlaxoSmithKline | For profit | 2 | 0 | 1 | 2001 |
3 organizations
Page 1 / 1